Autism spectrum disorder. Autistic disorder
Conditions
Interventions
Intervention 1: Control group: Patients will receive risperidone and placebo for 12 weeks. Risperidone will be started at a starting dose of 0.5 mg per day and will be increased by 0.5 mg every 7 days
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 12 Years
Inclusion criteria
Inclusion criteria: Age between 5-12 years Diagnosis of autism spectrum disorder based on DSM-V Patients who have specific behavioral problems such as aggression, hyperactivity, unusual, and stereotyped behaviors
Exclusion criteria
Exclusion criteria: An active medical disease Diagnosis of another psychological disorder in DSM History of previous sensitivity and intolerance to nanocurcumin History of seizures and liver disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Irritability. Timepoint: At the beginning of the study and at weeks 4, 8, and 12. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C). | — |
Secondary
| Measure | Time frame |
|---|---|
| Lethargy (a kind of state of confusion, unresponsiveness, lack of energy, and abnormal drowsiness), Hyperactivity, Stereotyped behavior, Quality of speech. Timepoint: At the beginning of the study and at weeks 4, 8, and 12. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed